What MSM is and where it's sourced
MSM is the common name for methylsulfonylmethane, also written as dimethyl sulfone. The chemical structure is a sulfur atom double-bonded to two oxygen atoms with two methyl groups attached — an organosulfur compound that occurs naturally in trace amounts in fruits, vegetables, grains, milk, and certain meats. The compound is also a downstream metabolite of dimethyl sulfoxide (DMSO), which is itself a documented compound with industrial and pharmaceutical uses.
Commercial MSM for supplement and pet food use is synthesized industrially via the oxidation of DMSO. The resulting MSM is chemically identical to natural MSM and is purified to either food-grade or pharmaceutical-grade specifications depending on intended application. Most pet food MSM is feed-grade, blended with glucosamine and chondroitin in joint-support formulations or sold separately as a topper supplement.
The joint-support marketing positioning
MSM is marketed for joint support based on three claimed mechanisms: contribution of bioavailable sulfur for endogenous glycosaminoglycan synthesis (cartilage matrix), antioxidant and anti-inflammatory activity at the cellular level, and support of methyl-group donor function in cellular biochemistry. Each claimed mechanism has some in-vitro or biochemical support but variable translation to clinical outcomes.
In commercial pet food labeling, MSM appears most commonly in the "added joint support" or "advanced mobility" tier of senior and large-breed formulas, often paired with glucosamine and chondroitin in the well-known "joint trio." The standard pairing reflects the marketing convention that consumers expect to see all three together rather than independent evidence that the combination outperforms simpler formulations.
Evidence summary — human studies vs canine studies
Human osteoarthritis evidence for MSM is moderate. NIH MedlinePlus rates oral MSM as "possibly effective" for OA based primarily on two double-blind randomized trials: Brien 2008 (Osteoarthritis Cartilage), which reported significant pain reduction at 3,000-6,000 mg/day in human knee OA patients, and Kim 2006 (Osteoarthritis Cartilage), which reported similar effects at comparable doses. The Usha 2004 (Clin Drug Investig) trial reported synergistic pain reduction from combined glucosamine + MSM versus glucosamine alone in human knee OA.
Canine clinical evidence is much thinner. The AAHA 2022 Pain Management Guidelines group joint nutraceuticals (glucosamine, chondroitin, MSM, green-lipped mussel) collectively as having low-quality evidence for canine OA pain reduction — meaning some studies show effect, others do not, and the body of evidence does not support strong clinical recommendation. The Pye 2024 (JVIM) review of canine joint nutraceuticals reaches the same conclusion: well-tolerated, biochemically plausible, but modest clinical effect sizes.
The Roush 2010 (JAVMA) prospective canine osteoarthritis trial reported clinically meaningful pain reduction from omega-3 fatty acid supplementation that exceeded typical glucosamine-chondroitin-MSM trial outcomes. AAHA 2022 reflects this evidence asymmetry.
The glucosamine-chondroitin-MSM trio in joint formulas
The "glucosamine-chondroitin-MSM trio" is a marketing convention reinforced by consumer expectation more than by independent evidence that the combination outperforms simpler formulations. Major therapeutic joint diets (Hill's J/D, Royal Canin Mobility Support) include MSM as part of broader anti-inflammatory formulation strategies that also feature substantial omega-3 EPA + DHA inclusion, controlled caloric density for body-condition management, and weight-management calorie targets. The clinical effect of these diets is therefore not attributable to MSM alone but to the combined formulation.
Standalone MSM at supplemental doses (typically 50-100 mg per kg body weight per day) is also sold as a separate joint-support topper. The AAHA 2022 evidence rating applies regardless of whether MSM is delivered via diet or as a separate supplement.
How KibbleIQ scores MSM
The KibbleIQ Dry Kibble Rubric v15 treats MSM similarly to chondroitin sulfate: a positive-but-modest ingredient when present at meaningful inclusion in joint-support contexts. Its presence does not significantly upgrade a formula's overall score, and its absence does not penalize a formula. The bigger drivers of joint-support score in our rubric are omega-3 fatty acids from marine sources at clinically relevant doses (EPA + DHA) and overall caloric density appropriate for body-condition management.
For comparable explainers on adjacent joint-support ingredients, see our glucosamine explainer, chondroitin sulfate explainer, and omega-3 fatty acids explainer. To check your current bag, paste the ingredient list into the KibbleIQ analyzer.